ImageneBio Reports $10.6 Million Net Loss in Q1 2026, Increased Operating Expenses

ImageneBio, Inc. reported a net loss of $10.6 million for the first quarter of 2026, a significant increase from the $6.1 million loss recorded in the same period of the previous year. The company's total operating expenses rose to $12.1 million, up from $6.8 million in the first quarter of 2025, primarily driven by increased research and development costs associated with its lead product candidate, IMG-007, and higher general and administrative expenses. The company did not generate any license revenue during this quarter, a decrease from $800,000 in the prior year, following the divestiture of its non-IMG-007 business.

In terms of financial position, ImageneBio's cash and cash equivalents decreased to $76.0 million as of March 31, 2026, down from $94.5 million at the end of 2025. The company also reported total assets of $136.7 million, a decline from $153.0 million at the end of the previous fiscal year. The increase in operating expenses was attributed to heightened clinical trial activities and personnel-related costs, including stock-based compensation, as the company continues to advance its clinical programs.

Strategically, ImageneBio underwent a significant transformation following its merger with Inmagene Biopharmaceuticals on July 25, 2025. This merger resulted in the divestiture of non-IMG-007 assets and a rebranding from Ikena Oncology, Inc. to ImageneBio, Inc. The company is now focused solely on the development of IMG-007, a monoclonal antibody targeting OX40 for the treatment of atopic dermatitis and alopecia areata, among other potential indications. The company has initiated a Phase 2b clinical trial for IMG-007, with topline data expected in late 2027.

Operationally, the company has seen an increase in its workforce, which has contributed to the rise in general and administrative expenses. As of March 31, 2026, ImageneBio had 11.2 million shares outstanding, reflecting a significant increase in share count due to the merger and subsequent equity financing activities. The company also raised $30 million in April 2026 through a private placement of pre-funded warrants, which is expected to support its operations for at least the next 12 months.

Looking ahead, ImageneBio anticipates continued investment in the development of IMG-007 and plans to initiate a Phase 2 study for alopecia areata by the end of 2026. The company acknowledges the need for substantial additional funding to support its ongoing operations and clinical development efforts, emphasizing the uncertainty surrounding future revenue generation and the potential for further equity offerings or collaborations to secure necessary capital.